Cargando…

Prolactinomas Resistant to Treatment With Dopamine Agonists: Long-Term Follow-Up of Six Cases

Introduction: Prolactinomas are preferentially treated with dopamine agonists. However, a few adenomas are resistant to this treatment. Objective: To evaluate the characteristics of patients with resistance to dopamine agonists in the long-term. Method: A retrospective study of six cases was made. P...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gonzaga, Maria de Fátima de Magalhães, de Castro, Lucas Faria, Naves, Luciana Ansaneli, Mendonça, José Luiz, Oton de Lima, Benicio, Kessler, Iruena, Casulari, Luiz Augusto
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2018
Materias:	Endocrinology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6277870/ https://www.ncbi.nlm.nih.gov/pubmed/30542321 http://dx.doi.org/10.3389/fendo.2018.00625

Ejemplares similares

Giant cabergoline-resistant prolactinoma in a man who presented with a psychotic episode during treatment: a case report
por: Casulari, Luiz Augusto, et al.
Publicado: (2019)

The Effect of Cognitive-Behavioral Therapy on Acromegalics After a 9-Month Follow-Up
por: Kunzler, Lia Silvia, et al.
Publicado: (2019)

The Mechanism and Pathways of Dopamine and Dopamine Agonists in Prolactinomas
por: Liu, Xiaoshuang, et al.
Publicado: (2019)

Dopamine agonist therapy for prolactinomas: do we need to rethink the place of surgery in prolactinoma management?
por: De Sousa, Sunita M C
Publicado: (2022)

Experience with Dopamine Agonists in the Treatment of Prolactinomas
por: Barabash, Nadiya Ye., et al.
Publicado: (2022)

Predictors of dopamine agonist resistance in prolactinoma patients
por: Vermeulen, Elle, et al.
Publicado: (2020)

Prognostic Value of Invasion, Markers of Proliferation, and Classification of Giant Pituitary Tumors, in a Georeferred Cohort in Brazil of 50 Patients, with a Long-Term Postoperative Follow-Up
por: Zakir, Juliano Coelho de Oliveira, et al.
Publicado: (2016)

Geographical information system (GIS) as a new tool to evaluate epidemiology based on spatial analysis and clinical outcomes in acromegaly
por: Naves, Luciana Ansaneli, et al.
Publicado: (2013)

Pituitary surgery for small prolactinomas as an alternative to treatment with dopamine agonists
por: Babey, Muriel, et al.
Publicado: (2010)

Dopamine agonist resistant prolactinomas: any alternative medical treatment?
por: Souteiro, P., et al.
Publicado: (2019)

PMON169 D2R Expression in Dopamine-Agonist Resistant Prolactinomas
por: Levine, Alice, et al.
Publicado: (2022)

SUN-448 Giant Prolactinomas: A Follow-Up of 25 Years with Dopamine Agonists
por: Mallea Gil, Susana, et al.
Publicado: (2019)

Case Report: Temozolomide Treatment of Refractory Prolactinoma Resistant to Dopamine Agonists
por: Tang, Hao, et al.
Publicado: (2021)

FRI303 PRL-R Variants Are Not Only Associated With Prolactinomas But Also With Dopamine Agonist Resistance
por: de Castro Moreira, Andrea Ramos, et al.
Publicado: (2023)

Long-term Outcome of Microscopic Transsphenoidal Surgery for Prolactinomas as an Alternative to Dopamine Agonists
por: Park, Kawngwoo, et al.
Publicado: (2021)

Effect of Tamoxifen on the Management of Dopamine Agonist-Resistant Prolactinomas: A Systematic Review
por: Bazuhair, Tuqa, et al.
Publicado: (2023)

Lower PRDM2 expression is associated with dopamine-agonist resistance and tumor recurrence in prolactinomas
por: Gao, Hua, et al.
Publicado: (2015)

Metabolic effects of dopamine agonists in patients with prolactinomas: a systematic review and meta-analysis
por: Byberg, Sarah, et al.
Publicado: (2019)

The recurrence of prolactinoma after withdrawal of dopamine agonist: a systematic review and meta-analysis
por: Zou, Yunzhi, et al.
Publicado: (2021)

Change in Insulin Sensitivity and Lipid Profile After Dopamine Agonist Therapy in Patients With Prolactinoma
por: Khalil, Ghayyur, et al.
Publicado: (2021)

Morbid Obesity Due to Prolactinoma and Significant Weight Loss After Dopamine Agonist Treatment
por: Ali, Muzaffar, et al.
Publicado: (2021)

Controversial issues in the management of hyperprolactinemia and prolactinomas – An overview by the Neuroendocrinology Department of the Brazilian Society of Endocrinology and Metabolism
por: Vilar, Lucio, et al.
Publicado: (2018)

SAT-435 Optimization of Pharmacological Treatment of Acromegaly: Impact on IGF-1 Levels Comparing Isolated Octreotide LAR and Combined Pharmacological Therapy
por: Naves, Luciana, et al.
Publicado: (2019)

Status epilepticus induced by treatment with dopamine agonist therapy for giant prolactinoma: a case report
por: Koguchi, Motofumi, et al.
Publicado: (2019)

SAT-247 Use of Double Dopamine Agonists in Giant Prolactinomas: A Series of 6 Cases
por: Kuan, Yueh Chien
Publicado: (2020)

MON-293 The Prevalence of Impulse Control Disorders in Patients with Acromegaly and Prolactinomas Treated with Dopamine Agonists
por: Ozkaya, Hande Mefkure, et al.
Publicado: (2020)

Delayed presentation of late-onset cerebrospinal fluid rhinorrhoea following dopamine agonist therapy for giant prolactinoma
por: Prague, J K, et al.
Publicado: (2014)

Pituitary Prolactinoma with Amyloid Deposits: Surgery or Dopamine Agonists? Review of Previous Reports and New Recommendations for Management
por: Prabhu, Santosh, et al.
Publicado: (2019)

The side effects of dopamine receptor agonist drugs in Chinese prolactinoma patients: a cross sectional study
por: Ke, Xiaoan, et al.
Publicado: (2022)

THU029 Subcutaneous Self-injections Of Lanreotide Is a Good Alternative For Acromegalic Patients With Long COVID Treated With Anticoagulants
por: Rosa, Isabella Naves, et al.
Publicado: (2023)

Successful Improvement of Metabolic Disorders, Including Osteopenia, by a Dopamine Agonist in a Male Patient with Macro-Prolactinoma
por: Takeno, Ayumu, et al.
Publicado: (2016)

The role of MAPK11/12/13/14 (p38 MAPK) protein in dopamine agonist-resistant prolactinomas
por: Wang, Shuman, et al.
Publicado: (2021)

Are dopamine agonists still the first-choice treatment for prolactinoma in the era of endoscopy? A systematic review and meta-analysis
por: Cai, Xiangming, et al.
Publicado: (2022)

FRI305 Impulse Control Disorders In Patients With Prolactinomas And Non-Functioning Pituitary Adenomas Treated With Dopamine Agonists
por: Kolitz, Tamara, et al.
Publicado: (2023)

Antenatal corticosteroids may contribute to illness in children in the future
por: Casulari, Luiz Augusto, et al.
Publicado: (2022)

Is prolactin receptor signaling a target in dopamine-resistant prolactinomas?
por: Ferraris, Jimena
Publicado: (2023)

Classic cardiovascular risk factors improve in very elderly hypopituitary patients treated on standard hormone replacement in long term follow- up
por: Rosa, Isabella Naves, et al.
Publicado: (2021)

SAT-455 Analysis of a Group of Prolactinomas Resistant to Treatment with Dopamine Agonists at a University Hospital in Buenos Aires, Argentina
por: Gonzalez Pernas, Mariana, et al.
Publicado: (2019)

PMON78 Improvement in Resistant Hypogonadism with use of Clomiphene in Prolactinomas Treated with Dopamine Agonist: A Case Study and Review of Literature
por: Singh, Julie, et al.
Publicado: (2022)

SUN-300 Improvement in Cardiovascular Risk Factors in Long Term Follow up of Hypopituitary Septagenarian and Octagenarian Patients
por: Rosa, Isabella Naves, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_k3l8ibbi60rcadahf6js4aq219